Baxter, Halozyme win FDA OK for HyQvia
This article was originally published in Scrip
Executive Summary
The FDA late on 12 September approved Baxter's HyQvia's (immune globulin infusion 10% (human)/recombinant human hyaluronidase), a subcutaneous treatment for adults with primary immunodeficiency, a group of more than 175 disorders in which part of the body's immune system is missing or does not function properly.
You may also be interested in...
Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.